Ten challenges for TB biomarkers

Tom H M Ottenhoff; Jerrold J. Ellner; Stefan H E Kaufmann

doi:10.1016/S1472-9792(12)70007-0

Ten challenges for TB biomarkers

Tom H M Ottenhoff, Jerrold J. Ellner, Stefan H E Kaufmann

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

The availability of tuberculosis (TB) biomarkers of protection (or: "surrogate endpoints of protection against active TB" (Biomarkers Definitions Working Group, 2001)) would greatly facilitate and accelerate TB vaccine development and increase the likelihood of success. TB biomarkers of protection could determine which vaccines in clinical trials are the most efficacious; which vaccine candidates and strategies are the most promising in early stages in the preclinical development pipeline (including relevant antigens, antigen delivery, live vaccines); and which combination vaccines (prime/boost) would be the most effective. Here we discuss ten major challenges for biomarker identification and validation in TB. Current major roadblocks and critical limitations in understanding TB pathogenesis are highlighted, and new solutions and strategies proposed.

Original language	English (US)
Journal	Tuberculosis
Volume	92
Issue number	SUPPL.1
DOIs	https://doi.org/10.1016/S1472-9792(12)70007-0
State	Published - Mar 2012
Externally published	Yes

Keywords

Biomarkers
Correlates
Tuberculosis
Vaccination

ASJC Scopus subject areas

Microbiology
Immunology
Infectious Diseases
Microbiology (medical)

Access to Document

10.1016/S1472-9792(12)70007-0

Cite this

@article{a1e9e62c29ad481f88809a0b26e52f7b,

title = "Ten challenges for TB biomarkers",

abstract = "The availability of tuberculosis (TB) biomarkers of protection (or: {"}surrogate endpoints of protection against active TB{"} (Biomarkers Definitions Working Group, 2001)) would greatly facilitate and accelerate TB vaccine development and increase the likelihood of success. TB biomarkers of protection could determine which vaccines in clinical trials are the most efficacious; which vaccine candidates and strategies are the most promising in early stages in the preclinical development pipeline (including relevant antigens, antigen delivery, live vaccines); and which combination vaccines (prime/boost) would be the most effective. Here we discuss ten major challenges for biomarker identification and validation in TB. Current major roadblocks and critical limitations in understanding TB pathogenesis are highlighted, and new solutions and strategies proposed.",

keywords = "Biomarkers, Correlates, Tuberculosis, Vaccination",

author = "Ottenhoff, {Tom H M} and Ellner, {Jerrold J.} and Kaufmann, {Stefan H E}",

year = "2012",

month = mar,

doi = "10.1016/S1472-9792(12)70007-0",

language = "English (US)",

volume = "92",

journal = "Tuberculosis",

issn = "1472-9792",

publisher = "Churchill Livingstone",

number = "SUPPL.1",

}

TY - JOUR

T1 - Ten challenges for TB biomarkers

AU - Ottenhoff, Tom H M

AU - Ellner, Jerrold J.

AU - Kaufmann, Stefan H E

PY - 2012/3

Y1 - 2012/3

N2 - The availability of tuberculosis (TB) biomarkers of protection (or: "surrogate endpoints of protection against active TB" (Biomarkers Definitions Working Group, 2001)) would greatly facilitate and accelerate TB vaccine development and increase the likelihood of success. TB biomarkers of protection could determine which vaccines in clinical trials are the most efficacious; which vaccine candidates and strategies are the most promising in early stages in the preclinical development pipeline (including relevant antigens, antigen delivery, live vaccines); and which combination vaccines (prime/boost) would be the most effective. Here we discuss ten major challenges for biomarker identification and validation in TB. Current major roadblocks and critical limitations in understanding TB pathogenesis are highlighted, and new solutions and strategies proposed.

AB - The availability of tuberculosis (TB) biomarkers of protection (or: "surrogate endpoints of protection against active TB" (Biomarkers Definitions Working Group, 2001)) would greatly facilitate and accelerate TB vaccine development and increase the likelihood of success. TB biomarkers of protection could determine which vaccines in clinical trials are the most efficacious; which vaccine candidates and strategies are the most promising in early stages in the preclinical development pipeline (including relevant antigens, antigen delivery, live vaccines); and which combination vaccines (prime/boost) would be the most effective. Here we discuss ten major challenges for biomarker identification and validation in TB. Current major roadblocks and critical limitations in understanding TB pathogenesis are highlighted, and new solutions and strategies proposed.

KW - Biomarkers

KW - Correlates

KW - Tuberculosis

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84858737486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858737486&partnerID=8YFLogxK

U2 - 10.1016/S1472-9792(12)70007-0

DO - 10.1016/S1472-9792(12)70007-0

M3 - Article

C2 - 22441153

AN - SCOPUS:84858737486

SN - 1472-9792

VL - 92

JO - Tuberculosis

JF - Tuberculosis

IS - SUPPL.1

ER -

Ten challenges for TB biomarkers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this